AI assistant
Sending…
Lite Strategy, Inc. — Director's Dealing 2021
Jul 7, 2021
34267_dirs_2021-07-06_cff31ed2-98c6-41b1-a653-5d47547d6837.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: MEI Pharma, Inc. (MEIP)
CIK: 0001262104
Period of Report: 2021-07-01
Reporting Person: Cohen Cheryl (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-07-01 | Stock Option (Right to Buy) | $2.95 | A | 50000 | Acquired | 2031-07-01 | Common Stock (50000) | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $3.49 | 2030-07-02 | Common Stock (50000) | 50000 | Direct |
| Stock Option (Right to Buy) | $1.71 | 2030-04-10 | Common Stock (30000) | 30000 | Direct |
Footnotes
F1: The options will vest in equal monthly installments over twelve months.
F2: All of such options are presently exercisable.
F3: 20,000 options will vest in equal monthly installments over thirty-six months from April 10, 2020 and 10,000 options shall vest in equal monthly installments over twelve months from April 10, 2020.
More from Lite Strategy, Inc.
Regulatory Filings
2026
May 13
Interim / Quarterly Report
2026
May 13
Regulatory Filings
2026
Feb 17
Interim / Quarterly Report
2026
Feb 17
Director's Dealing
2026
Feb 12
Regulatory Filings
2026
Feb 12
Annual Report
2025
Dec 30
Regulatory Filings
2025
Dec 30
Proxy Solicitation & Information Statement
2025
Dec 30
Regulatory Filings
2025
Dec 30